Xcout Intel
OverT Bio, Inc.
OverT Bio, Inc. is a New York-based biotechnology company that pioneers next-generation cellular therapies and biologics at scale. The company focuses on developing effective and safe cellular treatments for solid tumors.
Subscribe to see OverT Bio, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
OverT Bio, Inc. at a glance
OverT Bio, Inc. is a biotechnology company headquartered in United States. Its most recent funding round, Seed, raised $120,000 in November 2024. Xcout tracks 3 named people at OverT Bio, Inc., including Mat Legut (Co-Founder and CEO).
OverT Bio, Inc. leadership
- Mat LegutCo-Founder and CEO
- Neville SanjanaCo-Founder
- Sara ChoiDirector
OverT Bio, Inc. funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | $120,000 | 9 named | |
| Seed | $16M | 1 named | |
| SEC Form D filing | $16M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
OverT Bio, Inc. competitors
A few of OverT Bio, Inc.'s closest competitors — see the full list of competitors and alternatives →
Pan Cancer T develops pioneering T-cell receptor (TCR-T) cell therapies designed to empower patients' immune systems to target and overcome solid tumors. The company utilizes proprietary gene engineering to enhance T-cell fitness and persistence against unique cancer-specific intracellular targets.
ImmPACT Bio is a biotechnology company developing next-generation cancer immunotherapies, including dual-targeted CAR T-cell therapies. Its programs are intended to serve patients with B-cell malignancies and potentially other cancers, including solid tumors.
ImmuXell Biotechnology is a clinical-stage biopharmaceutical innovation company headquartered in Shanghai, China. Founded in 2021, the company focuses on developing novel immune cell therapies targeted at treating solid tumor cancers.
OneChain Immunotherapeutics is a biotechnology company based in Barcelona focused on the development of CAR-T cell therapies and in vivo platforms for cancer immunotherapy.
Orca Bio is a late-stage biotechnology company developing high-precision cell therapies. These therapies are designed for the treatment of cancer and autoimmune diseases, with a facility located in Sacramento.
Founded in 2018 and headquartered in San Diego, IconOVir Bio, Inc. is a preclinical-stage biotechnology company that specializes in creating therapies to target cancer cells using engineered viruses.
Get OverT Bio, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on OverT Bio, Inc. in Xcout Intel
- 3 named people with titles, LinkedIn and board committees
- 3 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access